MX2022004212A - Moduladores de atf6 y usos de los mismos. - Google Patents
Moduladores de atf6 y usos de los mismos.Info
- Publication number
- MX2022004212A MX2022004212A MX2022004212A MX2022004212A MX2022004212A MX 2022004212 A MX2022004212 A MX 2022004212A MX 2022004212 A MX2022004212 A MX 2022004212A MX 2022004212 A MX2022004212 A MX 2022004212A MX 2022004212 A MX2022004212 A MX 2022004212A
- Authority
- MX
- Mexico
- Prior art keywords
- atf6
- modulators
- compounds
- treatment
- diseases
- Prior art date
Links
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 title 1
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101000835023 Homo sapiens Transcription factor A, mitochondrial Proteins 0.000 abstract 1
- 102100026155 Transcription factor A, mitochondrial Human genes 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 201000011531 vascular cancer Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Liquid Crystal Substances (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos como moduladores del Factor 6 de Transcripción de Activación (ATF6). Los compuestos pueden encontrar uso como agentes terapéuticos para el tratamiento de enfermedades o trastornos mediados por ATF6 y pueden encontrar uso particular en el tratamiento de infecciones virales, enfermedades neurodegenerativas, enfermedades vasculares o cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913126P | 2019-10-09 | 2019-10-09 | |
| PCT/EP2020/078478 WO2021069701A1 (en) | 2019-10-09 | 2020-10-09 | Atf6 modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004212A true MX2022004212A (es) | 2022-06-08 |
Family
ID=72852648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004212A MX2022004212A (es) | 2019-10-09 | 2020-10-09 | Moduladores de atf6 y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220389001A1 (es) |
| EP (1) | EP4041727A1 (es) |
| JP (1) | JP2022552231A (es) |
| KR (1) | KR20220086597A (es) |
| CN (2) | CN115135645B (es) |
| AU (1) | AU2020361484A1 (es) |
| BR (1) | BR112022006734A2 (es) |
| CA (1) | CA3156839A1 (es) |
| CL (1) | CL2022000894A1 (es) |
| IL (1) | IL291963A (es) |
| MX (1) | MX2022004212A (es) |
| WO (1) | WO2021069701A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202009570SA (en) | 2018-04-06 | 2020-10-29 | Black Belt Tx Ltd | Atf6 inhibitors and uses thereof |
| CN118127010A (zh) * | 2024-02-06 | 2024-06-04 | 佛山市南海区人民医院 | 一种抑制ATF6α基因的siRNA分子及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202009570SA (en) * | 2018-04-06 | 2020-10-29 | Black Belt Tx Ltd | Atf6 inhibitors and uses thereof |
| JP2021522253A (ja) * | 2018-04-25 | 2021-08-30 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
-
2020
- 2020-10-09 BR BR112022006734A patent/BR112022006734A2/pt not_active Application Discontinuation
- 2020-10-09 KR KR1020227015423A patent/KR20220086597A/ko active Pending
- 2020-10-09 CA CA3156839A patent/CA3156839A1/en active Pending
- 2020-10-09 US US17/767,031 patent/US20220389001A1/en active Pending
- 2020-10-09 EP EP20790252.9A patent/EP4041727A1/en active Pending
- 2020-10-09 WO PCT/EP2020/078478 patent/WO2021069701A1/en not_active Application Discontinuation
- 2020-10-09 MX MX2022004212A patent/MX2022004212A/es unknown
- 2020-10-09 JP JP2022521085A patent/JP2022552231A/ja active Pending
- 2020-10-09 CN CN202080082798.2A patent/CN115135645B/zh active Active
- 2020-10-09 CN CN202411809060.8A patent/CN119823112A/zh active Pending
- 2020-10-09 AU AU2020361484A patent/AU2020361484A1/en active Pending
- 2020-10-09 IL IL291963A patent/IL291963A/en unknown
-
2022
- 2022-04-07 CL CL2022000894A patent/CL2022000894A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115135645A (zh) | 2022-09-30 |
| JP2022552231A (ja) | 2022-12-15 |
| WO2021069701A1 (en) | 2021-04-15 |
| US20220389001A1 (en) | 2022-12-08 |
| CL2022000894A1 (es) | 2023-01-13 |
| IL291963A (en) | 2022-06-01 |
| CA3156839A1 (en) | 2021-04-15 |
| AU2020361484A1 (en) | 2022-05-12 |
| AU2020361484A9 (en) | 2023-06-29 |
| EP4041727A1 (en) | 2022-08-17 |
| KR20220086597A (ko) | 2022-06-23 |
| CN119823112A (zh) | 2025-04-15 |
| CN115135645B (zh) | 2024-12-27 |
| BR112022006734A2 (pt) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| CL2018002516A1 (es) | Inhibidores de mcl-1 indólicos sustituidos. | |
| PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| SV2017005557A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX2019001575A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| MX2024013040A (es) | Pirfenidona enriquecida con deuterio y metodos para su uso | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2023001580A1 (es) | Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección | |
| MX2022004212A (es) | Moduladores de atf6 y usos de los mismos. | |
| BR112023018237A2 (pt) | Fenalquilaminas e métodos para fabricação e uso das mesmas | |
| CL2021000930A1 (es) | Piridazinas novedosas | |
| CL2022002589A1 (es) | Tratamiento de trastornos respiratorios | |
| MX2022004219A (es) | Moduladores de atf6 y usos de los mismos. | |
| MX2021009767A (es) | Moleculas de union de fmcr y usos de las mismas. | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |